Phase 1 Study of the Safety and Efficacy of ATA188, an Off-the-shelf, Allogeneic eic 0.6 (ic)-32 n1A188, an Off

- Two composite clinical outcome scales were assessed. The first composite scale focuses on measuring sustained disability improvement (SDI) via an adapted outcome measure used in a recent phase 3 study (NCT02936037), the first phase 3 study to have this endpoint accepted for use, which utilizes improvement in EDSS and T25FW from baseline

Sustained Disability Improvement



EDSS = expanded disability status scale; T25FW = timed 25-foot walk.

Table 1. Patient Baseline Characteristics[a] – All Subjects Receiving at Least One Dose

[a]Baseline characteristics that differed among cohorts are presented. Analyzed baseline characteristics included sex, ethnicity, race, age, weight, height, BMI, BSA, time from initial diagnosis, prior MS medication, gadolinium enhancing lesion count, and normalized brain volume.
[b]Seven patients were enrolled in cohort 4. One grade 3 event of MS relapse in Cohort 4 was assessed as possibly treatment-related. The event occurred 7 days after dosing in the setting of ongoing upper respiratory tract infection symptoms and possible dental infection.